Nanosonics Limited Commercialising innovative solutions to global healthcare challenges
Overview
.jpg)
Nanosonics is an ASX-listed company (ASX: NAN) located in Alexandria, Sydney. Nanosonics was founded in 2000 and publicly listed on 17 May 2007.
The Company owns, develops and commercialises intellectual property relating to its unique disinfection and sterilisation technologies, which are suited to a variety of markets, including healthcare, food processing, room and space decontamination and manufacturing.
The Company’s disinfection and sterilisation technologies provide the unique ability to produce safe, non-toxic, fast and environmentally friendly solutions.
Current methods of disinfection and sterilisation are limited in their ability to kill infections agents, which can lead to serious contagious illnesses. Nanosonics technologies are able to kill the most resilient micro-organisms and mark the beginning of new and unique standards. Compared to existing standards, Nanosonics introduces two new dimensions of disinfection and sterilisation based on the Company’s platform technologies:
Nanosonics intellectual property is well protected by a combination of patent families, trademarks and proprietary know-how, which include its platform technologies. This and the fact that the Company’s technologies are transferable and highly scalable to other applications, provides the foundation of Nanosonics product development and ensures long-term and sustainable competitive advantages.
Nanosonics is constantly exploring opportunities to expand its healthcare range of products and is also exploring a number of other markets for its proprietary technology such as room and space decontamination, food reprocessing and industrial applications.
Number of employees: 50
Main business focus/
Listing by sector:
- Medical Devices
Competitive Advantages
Nanosonics proprietary technologies are unique because high level disinfection and sterilisation can be achieved at very low temperatures and the entire process is environmentally friendly and safe. There is no exposure to harmful chemicals and the low operating temperature means potential applications are unlimited. Other unique benefits of the include short processing times and superior materials compatibility.
Current methods of disinfection and sterilisation are limited in their ability to kill infectious agents, which can lead to serious illnesses.
Hospital acquired infections such as Clostridium Difficile or MRSA present a widespread problem in today’s healthcare environment with a significant number of patients acquiring an infection annually. Hospital acquired infections are often caused by environmental organisms and have been linked to contaminated healthcare equipment.
Nanosonics’ innovative technologies are able to kill the most resilient micro-organisms and therefore mark the beginning of new and unique standards in disinfection and sterilisation.
Technology/IP
Nanosonics has developed a unique platform technology: the NanoNebulant technology. The process of this technology involves the production of an ultrafine mist, “NanoNebulant” i.e. particles in the sub micron range that contain a concentrated and highly effective biocide of highly concentrated hydrogen peroxide. The NanoNebulant can be quickly and evenly distributed in an area and applied to a number of instruments requiring High Level Disinfection+ or Sterilisation+.
At the end of the process, Nanosonics’ patented destructor breaks down the NanoNebulant leaving oxygen and water as the only by- products.
Contact Details
| Contact person | Mr Ron Weinberger |
|---|---|
| Job Title | CEO |
| Address | Unit 24 |
| 566 Gardeners Road | |
| City/Suburb | Alexandria |
| State | New South Wales |
| Operating State | National |
| reception@nanosonics.com.au | |
| Phone | +61 (0)2 9313 4399 |
| Fax | +61 (0)2 9317 5010 |
| Website | http://www.nanosonics.com.au |
